Generic Entry Reforms Gain Steam In Congress With House Committee Passage
Executive Summary
Bills to reign in petitions, pay-for-delay, product hopping, and patent thickets clear House Judiciary Committee. Legislation may have better shot at enactment this time around given bipartisan support in both House and Senate Committees.
You may also be interested in...
Pressure Builds For Biosimilars To Follow Lilly’s Lead After Insulin Price Cap
Biosimilar insulin producers are facing calls to improve patient affordability after Eli Lilly implemented a $35 price cap on copays for its insulins in the private market and for the uninsured.
Bipartisan Bills To Promote Drug Competition A Step Closer To Completion
The Preserving Access to Affordable Generics and Biosimilars Act and the Stop STALLING Act are both a step closer to becoming law after passing voice votes in the Senate Judiciary Committee.
FDA, USPTO In Middle Of Congressional Tug-Of-War Over Patents And Drug Pricing
Senators Hassan and Cassidy contend the lack of coordination between the two agencies may allow patent thickets to grow. Meanwhile, Sen. Tillis is pushing the agency to refute data alleging patents are to blame for high drug prices.